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Dear Editor in Chief,
With a great interest, we read a
recently published paper in Frontier in
Endocrinology journal by Vuolo et al.,
entitled “Vitamin D and Cancer” (Vuolo
et al., 2012). They skillfully reviewed the
role of vitamin D in all aspects of cancer
such as cancer prevention, immune sys-
tem and cancer, reverse effect of cancer
on vitamin D, and vitamin D status in
some important type of malignancy. This
issue is a hot topic in oncology, but in
this study there are some concerns which
undermine the results to make a definite
conclusion.
Although they concluded that “The
immune system seems to represent a rel-
evant target for the antineoplastic effects
of vitamin D,” (Vuolo et al., 2012)
they did not consider anti-neoplastic role
of activated form of vitamin D using
for immunotherapy of cancer. It was
recently shown that a group of vita-
min D-binding protein (DBP) so called
Gc protein is an important precursor
for activating macrophage as one of
the main innate immune cell for can-
cer immunotherapy (Nagasawa et al.,
2005). Although the aim of the review
by Vuolo et al. was the role of Vitamin
D in cancer, it was confirmed that the
level of vitamin D is related to Vitamin
D binding proteins (Carpenter et al.,
2012).
In normal tissue, when a neoplastic
tissue is arise, DBP is naturally activated
by glycosylation and transform to DBP-
derivedmacrophage-activating factor (Gc-
MAF) by b-galactosidase and sialidase of B
and T cells, respectively, which can activate
macrophage to phagocyte the neoplastic
cells. Group-specific component protein
(Gc) as DBP preserve vitamin D in body
fluids and put it available for tissues. But
an enzyme (a-N-acetylgalactosaminidase)
produced by neoplastic cells deactivate and
denaturize this factor and provide neo-
plastic cells to spread (Yamamoto and
Naraparaju, 1998; Ghanei et al., 2012). In
some clinical studies, Gc-MAF has suc-
cessfully been used for prostate, colorec-
tal, and breast cancer (Yamamoto and
Suyama, 2008; Yamamoto et al., 2008a,b).
Therefore, vitamin D has a prominent role
in natural tumorocidal activity of immune
system as an initial precursor.
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